Mercer Island, WA, United States of America

Philip D Greenberg

USPTO Granted Patents = 20 (Patent Applications = 15)

CIPO Patents = 3 (Patent Applications = 13)

EPO Patents = 7 (Patent Applications = 17)

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 356(Granted Patents)

Location History:

White Plains, NY (US) (1993 - 1994)
Seattle, WA (US) (2019 - 2021)
Mercer Island, WA (US) (1998 - 2024)

Company Filing History:

15 out of 289

Fred Hutchinson Cancer Center

patents

4 out of 31

The Mearl Corporation

patents

2 out of 56

Adaptive Biotechnologies Corporation

patents

4. 1 out of 8

Fred Hutchinson Cancer Research Center

patents

5. 1 out of 2,347

University of Illinois

patents

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448430 - High avidity WT1 T cell receptors and uses thereof (2025-10-21),

2. 12365906 - Immunomodulatory fusion proteins and uses thereof (2025-07-22),

3. 12012443 - Immunomodulatory fusion proteins and uses thereof (2024-06-18),

4. 11725210 - Immunomodulatory fusion proteins and uses thereof (2023-08-15),

5. 11458191 - Binding proteins specific for RAS neoantigens and uses thereof (2022-10-04),

6. 11382954 - Binding proteins specific for RAS neoantigens and uses thereof (2022-07-12),

7. 11041202 - Method of identifying human compatible T cell receptors specific for an antigenic target (2021-06-22),

8. 11026969 - High affinity T cell receptors and uses thereof (2021-06-08),

9. 10875904 - Enhanced affinity T cell receptors and methods for making the same (2020-12-29),

10. 10538572 - T cell immunotherapy specific for WT-1 (2020-01-21),

11. 10344075 - Engineered high-affinity human t cell receptors (2019-07-09),

12. 10208086 - Cyclin A1-targeted T-cell immunotherapy for cancer (2019-02-19),

13. 9751928 - Enhanced affinity T cell receptors and methods for making the same (2017-09-05),

14. 6040177 - High efficiency transduction of T lymphocytes using rapid expansion (2000-03-21),

15. 5827642 - Rapid expansion method ('REM') for in vitro propagation of T lymphocytes (1998-10-27),

Certainly! Here is an article about inventor Philip D Greenberg:

Title: Innovator Spotlight: Philip D Greenberg - A Pioneer in Immunomodulatory Fusion Proteins

Introduction:

Philip D Greenberg, a prolific inventor in the field of immunology, hails from Mercer Island, WA (US). With a remarkable portfolio of 14 patents to his name, Greenberg has been instrumental in developing groundbreaking immunomodulatory fusion proteins for the treatment of diseases like cancer and infectious diseases.

Latest Patents:

Greenberg's latest patents revolve around immunomodulatory fusion proteins, where an extracellular binding domain and an intracellular signaling domain work synergistically to modulate signals within host cells, particularly T cells. These proteins hold immense potential in delivering positive or costimulatory signals, contrary to inhibitory signals typically observed in such interactions. The applications of immune cells expressing these fusion proteins are particularly promising in the treatment of diseases like cancer and infectious diseases.

Career Highlights:

Greenberg has made significant contributions to the field of immunology through his work at the Fred Hutchinson Cancer Research Center and Fred Hutchinson Cancer Center. His dedication to developing novel therapies has led to a series of patents that have the potential to revolutionize the way certain diseases are treated.

Collaborations:

Throughout his career, Greenberg has collaborated with esteemed professionals in the field, including Thomas M Schmitt and Aude Georgiana Chapuis. These collaborations have been integral in advancing the research and development of immunomodulatory fusion proteins and their applications in treating various diseases.

Conclusion:

In conclusion, Philip D Greenberg stands out as a trailblazer in the realm of immunology, with a strong focus on developing innovative solutions to combat diseases using immunomodulatory fusion proteins. His visionary work continues to pave the way for new therapeutic approaches that hold immense promise for improving patient outcomes in the fight against cancer and infectious diseases.

This text is generated by artificial intelligence and may not be accurate.